Let a new month begin
2024 is flying by as we get into August. ReBlood Rx is making the most of our time working hard to bring our innovation to the world! We hope everyone’s August is as great as their July!
Thanks
Our team would like to thank NIH for accepting us into their Entrepreneurship Bootcamp! This program is designed to equip life science investigators and nascent companies with specialized innovation and entrepreneurship training. This will place us on a path to take advantage of NIH SBIR programs and help improve our commercialization potential.
Achievements
- Our team is extremely excited to be participating in the 757 Accelerate program put on by 757 Collabs. This 10-week accelerator focuses on companies who are “investor ready” and helps develop our deck and deal room as we meet with investors.
- ReBlood eagerly awaits a decision on a significant fee waiver from the FDA, saving ReBlood Rx over $900,000 dollars!
- ReBlood Rx is continuing to learn as much as we can from the mentors and instructor of the VentureWell Stage 2 program, which is providing us additional support and resources to further our development and scaling efforts.
- Thank you to all who keep up with our journey on LinkedIn! If you are not following our page, visit us here to stay up to date!
Opportunities
- If you or someone you know is willing to share your experiences with HBOC use in the Veterinarian Industry, we would love to hear your thoughts.
- Now that we are pitching to potential investors, if you would like to review our deck or listen to our pitch and provide us with constructive feedback, please let us know!
- ReBlood Rx is eager to learn and grow! If you know of any accelerator opportunities, we would love to hear about them.
- ReBlood Rx is looking for help sourcing grants in the DoD, NSF, or NHLBI ecosystem. If you know of any please forward them over!
Thank you all for your continued support!